| Literature DB >> 22021758 |
Emma S Nyman1, Sonja Sulkava, Pia Soronen, Jouko Miettunen, Anu Loukola, Virpi Leppä, Matti Joukamaa, Pirjo Mäki, Marjo-Riitta Järvelin, Nelson Freimer, Leena Peltonen, Juha Veijola, Tiina Paunio.
Abstract
Objectives Depression is a worldwide leading cause of morbidity and disability. Genetic studies have recently begun to elucidate its molecular aetiology. The authors investigated candidate genes of monoamine neurotransmission and early environmental risk factors for depressiveness in the genetically isolated population-based Northern Finland Birth Cohort 1966 (12 058 live births). Design The authors ascertained and subdivided the study sample (n=5225) based on measures of early development and of social environment, and examined candidate genes of monoamine neurotransmission, many of which have shown prior evidence of a gene-environment interaction for affective disorders, namely SLC6A4, TPH2, COMT, MAOA and the dopamine receptor genes DRD1-DRD5. Results and conclusion The authors observed no major genetic effects of the analysed variants on depressiveness. However, when measures of early development and of social environment were considered, some evidence of interaction was observed. Allelic variants of COMT interacted with high early developmental risk (p=0.005 for rs2239393 and p=0.02 for rs4680) so that the association with depression was detected only in individuals at high developmental risk group (p=0.0046 and β=0.056 for rs5993883-rs2239393-rs4680 risk haplotype CGG including Val158), particularly in males (p=0.0053 and β=0.083 for the haplotype CGG). Rs4274224 from DRD2 interacted with gender (p=0.017) showing a significant association with depressiveness in males (p=0.0006 and β=0.0023; p=0.00005 and β=0.069 for rs4648318-rs4274224 haplotype GG). The results support the role of genes of monoamine neurotransmission in the aetiology of depression conditional on environmental risk and sex, but not direct major effects of monoaminergic genes in this unselected population.Entities:
Year: 2011 PMID: 22021758 PMCID: PMC3191433 DOI: 10.1136/bmjopen-2011-000087
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Composition of the study sample from the NFBC 1966
| N | Hopkins Symptom Check List score>1.75 | Depression diagnosis | Measure of early development | Measure of social environment | |||||
| High-risk | Low-risk | nd | High-risk | Low-risk | nd | ||||
| Males | 2509 | 169 (7%) | 79 (3%) | 229 (9%) | 2094 (83%) | 186 (7%) | 912 (36%) | 1574 (63%) | 23 (0.9%) |
| Females | 2716 | 269 (10%) | 136 (5%) | 193 (7%) | 2328 (86%) | 195 (7%) | 1034 (38%) | 1649 (61%) | 33 (1.2%) |
| All | 5225 | 438 (8%) | 215 (4%) | 422 (8%) | 4422 (85%) | 381 (7%) | 1946 (37%) | 3223 (62%) | 56 (1.1%) |
There is prior support for using the Hopkins Symptom Check List score 1.75 as a cut-off when aiming to identify clinical depression.
Defined by the presence of two out of three possible indicators for high early developmental risk: low birth weight, late motor development and late development of speech.
Defined by the presence of two out of five possible indicators for high social risk environment: unwanted pregnancy, low socio-economic status, single parenthood, low level of education of mother and low activity for information retrieval by the mother. For further details, see text.
Both high early developmental and social risk present in 92 males (3,6%) and 67 females (2,4%).
Not defined.
Interaction (G×E) and correlation (rGE) between genetic variants of genes of monoamine neurotransmission and measures of early development (G×EDev, rGEDev)* and of social environment (G×ESoc, rGSoc)† and gender (G×Sex) on current depressive symptoms (Hopkins Symptom Check List score), and genetic association with Hopkins Symptom Check List score in the complete study sample from the NFBC 1966 (All)
| Gene | Gene name | Chromosome | SNP | Position/bp | Minor allele | MAF | P (G×EDev) | P (G×ESoc) | P (G×sex) | P (All) | P (rGEDev) | P (rGSoc) |
| SLC6A4 | Serotonin transporter | 17 | rs1906451 | 25539605 | G | 0.44 | 0.608 | 0.363 | 0.784 | 0.268 | 0.747 | |
| rs3794808 | 25555919 | A | 0.41 | 0.365 | 0.263 | 0.799 | 0.320 | 0.402 | 0.064 | |||
| rs140700 | 25567515 | A | 0.09 | 0.133 | 0.460 | 0.876 | 0.209 | 0.614 | ||||
| rs2066713 | 25575791 | A | 0.46 | 0.253 | 0.499 | 0.505 | 0.550 | 0.778 | 0.092 | |||
| rs8071667 | 25576899 | A | 0.15 | 0.473 | 0.682 | 0.122 | 0.606 | 0.961 | 0.827 | |||
| TPH2 | Tryptophan hydroxylase 2 | 12 | rs4131348 | 70610746 | G | 0.12 | 0.844 | 0.937 | 0.400 | 0.497 | 0.705 | 0.241 |
| rs2129575 | 70626340 | A | 0.22 | 0.787 | 0.682 | 0.432 | 0.423 | 0.173 | 0.298 | |||
| rs1386496 | 70637057 | G | 0.16 | 0.983 | 0.404 | 0.293 | 0.792 | 0.837 | 0.226 | |||
| rs2171363 | 70646531 | A | 0.43 | 0.762 | 0.983 | 0.814 | 0.692 | 0.940 | ||||
| rs10506645 | 70671767 | A | 0.23 | 0.996 | 0.756 | 0.102 | 0.789 | 0.888 | 0.721 | |||
| rs1386497 | 70678557 | C | 0.17 | 0.816 | 0.131 | 0.452 | 0.797 | 0.640 | 0.172 | |||
| rs1487276 | 70691326 | A | 0.21 | 0.888 | 0.088 | 0.838 | 0.908 | 0.591 | 0.219 | |||
| rs9325202 | 70693744 | A | 0.48 | 0.805 | 0.074 | 0.488 | 0.473 | 0.913 | 0.675 | |||
| rs1487275 | 70696559 | C | 0.37 | 0.972 | 0.054 | 0.625 | 0.861 | 0.638 | ||||
| rs1386483 | 70698761 | A | 0.47 | 0.574 | 0.090 | 0.326 | 0.437 | 0.294 | 0.625 | |||
| rs1872824 | 70716581 | A | 0.35 | 0.652 | 0.121 | 0.211 | 0.494 | 0.772 | 0.331 | |||
| COMT | Catechol- | 22 | rs6518591 | 18304021 | G | 0.16 | 0.688 | 0.255 | 0.919 | 0.303 | 0.150 | 0.385 |
| rs737866 | 18310109 | G | 0.18 | 0.853 | 0.755 | 0.623 | 0.489 | |||||
| rs1544325 | 18311668 | G | 0.48 | 0.318 | 0.376 | 0.192 | 0.822 | 0.999 | 0.931 | |||
| rs174675 | 18314051 | A | 0.29 | 0.465 | 0.278 | 0.580 | 0.958 | 0.724 | 0.532 | |||
| rs5993883 | 18317638 | C | 0.36 | 0.230 | 0.495 | 0.920 | 0.363 | 0.219 | ||||
| rs2239393 | 18330428 | G | 0.31 | 0.765 | 0.256 | 0.930 | 0.838 | 0.459 | ||||
| rs4680 | 18331271 | G | 0.45 | 0.956 | 0.501 | 0.346 | 0.412 | 0.498 | ||||
| rs4646316 | 18332132 | A | 0.18 | 0.205 | 0.165 | 0.933 | 0.521 | 0.392 | ||||
| rs165774 | 18332561 | A | 0.25 | 0.081 | 0.516 | 0.089 | 0.215 | 0.538 | 0.239 | |||
| rs165815 | 18339473 | G | 0.20 | 0.537 | 0.309 | 0.431 | 0.281 | 0.338 | 0.158 | |||
| rs887199 | 18341955 | A | 0.20 | 0.544 | 0.325 | 0.401 | 0.306 | 0.314 | 0.168 | |||
| rs2239395 | 18342203 | C | 0.02 | 0.144 | 0.655 | 0.153 | 0.390 | 0.224 | 0.664 | |||
| MAOA | Monoamine oxidase A | X | rs909525 | 43438146 | G | 0.45 | 0.559 | 0.871 | 0.554 | 0.165 | 0.255 | 0.932 |
| rs12843268 | 43458610 | A | 0.40 | 0.271 | 0.837 | 0.266 | 0.103 | 0.052 | 0.932 | |||
| rs6610845 | 43472954 | G | 0.41 | 0.232 | 0.795 | 0.263 | 0.170 | 0.060 | 0.524 | |||
| rs3027409 | 43491977 | C | 0.02 | 0.748 | 0.928 | 0.950 | 0.194 | 0.703 | 0.068 | |||
| rs6609257 | 43497652 | G | 0.50 | 0.848 | 0.320 | 0.470 | 0.077 | 0.075 | 0.898 | |||
| rs3027415 | 43499385 | G | 0.18 | 0.218 | 0.550 | 0.905 | 0.613 | 0.105 | 0.408 | |||
| DRD1 | Dopamine receptor D1 | 5 | rs265973 | 174793305 | G | 0.50 | 0.529 | 0.614 | 0.549 | 0.888 | 0.831 | |
| rs265974 | 174793846 | G | 0.35 | 0.391 | 0.612 | 0.912 | 0.659 | 0.066 | 0.859 | |||
| rs265976 | 174795026 | A | 0.23 | 0.578 | 0.707 | 0.915 | 0.826 | 0.077 | 0.933 | |||
| rs5326 | 174802802 | A | 0.19 | 0.615 | 0.886 | 0.852 | 0.588 | 0.273 | 0.197 | |||
| DRD2 | Dopamine receptor D2 | 11 | rs1800497 | 112776038 | A | 0.17 | 0.079 | 0.825 | 0.691 | 0.467 | 0.921 | 0.264 |
| rs2242592 | 112784640 | G | 0.37 | 0.757 | 0.466 | 0.283 | 0.736 | 0.143 | 0.393 | |||
| rs1076563 | 112801119 | C | 0.50 | 0.053 | 0.813 | 0.897 | 0.662 | 0.234 | 0.856 | |||
| rs2471857 | 112803549 | A | 0.17 | 0.518 | 0.494 | 0.823 | 0.901 | 0.884 | 0.126 | |||
| rs4620755 | 112814829 | A | 0.22 | 0.383 | 0.997 | 0.951 | 0.176 | 0.065 | 0.992 | |||
| rs7125415 | 112815891 | A | 0.19 | 0.084 | 0.389 | 0.789 | 0.231 | 0.163 | 0.947 | |||
| rs4648318 | 112818599 | G | 0.34 | 0.711 | 0.885 | 0.631 | 0.684 | 0.214 | 0.466 | |||
| rs4274224 | 112824662 | G | 0.24 | 0.067 | 0.777 | 0.536 | 0.766 | |||||
| rs4581480 | 112829684 | G | 0.07 | 0.184 | 0.521 | 0.210 | 0.082 | 0.760 | ||||
| rs7131056 | 112834984 | C | 0.49 | 0.564 | 0.795 | 0.413 | 0.964 | 0.622 | 0.138 | |||
| rs4938019 | 112846601 | G | 0.23 | 0.069 | 0.651 | 0.643 | 0.584 | 0.320 | 0.059 | |||
| rs12364283 | 112852165 | G | 0.08 | 0.280 | 0.504 | 0.441 | 0.861 | 0.633 | 0.804 | |||
| rs10891556 | 112857971 | A | 0.24 | 0.076 | 0.519 | 0.638 | 0.589 | 0.380 | 0.052 | |||
| rs6589377 | 112860946 | G | 0.17 | 0.286 | 0.617 | 0.061 | 0.552 | 0.502 | 0.915 | |||
| DRD3 | Dopamine receptor D3 | 3 | rs2087017 | 115324703 | G | 0.43 | 0.937 | 0.921 | 0.606 | 0.743 | 0.835 | 0.828 |
| rs2134655 | 115340891 | A | 0.28 | 0.454 | 0.554 | 0.129 | 0.507 | 0.209 | 0.330 | |||
| rs963468 | 115345577 | A | 0.38 | 0.809 | 0.777 | 0.902 | 0.608 | 0.609 | 0.580 | |||
| rs3773678 | 115352768 | A | 0.06 | 0.780 | 0.855 | 0.487 | 0.770 | 0.972 | 0.556 | |||
| rs2630351 | 115357749 | A | 0.03 | 0.954 | 0.144 | 0.168 | 0.999 | 0.811 | 0.211 | |||
| rs167771 | 115358965 | G | 0.18 | 0.862 | 0.638 | 0.406 | 0.514 | 0.416 | 0.966 | |||
| rs167770 | 115362252 | G | 0.31 | 0.260 | 0.911 | 0.298 | 0.694 | 0.593 | 0.982 | |||
| rs226082 | 115363703 | G | 0.31 | 0.261 | 0.911 | 0.301 | 0.690 | 0.594 | 0.983 | |||
| rs324029 | 115364313 | A | 0.31 | 0.259 | 0.913 | 0.296 | 0.722 | 0.593 | 0.964 | |||
| rs10934256 | 115368342 | A | 0.17 | 0.229 | 0.898 | 0.478 | 0.246 | 0.147 | 0.669 | |||
| rs1486009 | 115371222 | G | 0.12 | 0.721 | 0.667 | 0.745 | 0.571 | 0.387 | 0.600 | |||
| rs6280 | 115373505 | G | 0.33 | 0.159 | 0.485 | 0.141 | 0.667 | 0.386 | 0.880 | |||
| rs9825563 | 115382910 | G | 0.23 | 0.902 | 0.211 | 0.215 | 0.927 | |||||
| DRD4 | Dopamine receptor D4 | 11 | rs3758653 | 626399 | G | 0.23 | 0.300 | 0.752 | 0.249 | 0.980 | 0.322 | 0.905 |
| rs11246226 | 631191 | A | 0.49 | 0.749 | 0.748 | 0.166 | 0.925 | 0.908 | 0.097 | |||
| DRD5 | Dopamine receptor D5 | 4 | rs1878943 | 9375986 | A | 0.21 | 0.586 | 0.686 | 0.482 | 0.386 | 0.988 | 0.605 |
| rs13106539 | 9406801 | G | 0.39 | 0.735 | 0.062 | 0.067 | 0.532 | 0.384 | ||||
The analyses were performed using PLINK's linear and logistic regression models and interaction analysis. Empirical p values based on max(T) permutation are reported, with p values <0.05 shown in bold.
Defined by the presence of two out of three possible indicators for high early developmental risk: low birth weight, late motor development and late development of speech.
Defined by the presence of two out of five possible indicators for high social risk environment: unwanted pregnancy, low socio-economic status, single parenthood, low level of education of mother and low activity for information retrieval by the mother.
Minor allele frequency.
p=0.0364 (β=0.0414).
p=0.008 (β=0.0440).
p=0.042 (β=0.0320).
p=0.022 (β=–0.0396) in individuals at high risk group.
p>0.05 in both genders.
p=0.0006 (β=0.023) in males.
β=0.008.
β=0.012.
β=0.011.
β=0.022.
β=−0.
Haplotype analysis of COMT variants on current depressive symptoms (Hopkins Symptom Check List score) in individuals at high early developmental risk group (EDev)* from the NFBC 1966
| Gene | Variant | Haplotype | Frequency | Males and females at high risk EDev | Males at high risk EDev | Females at high risk EDev | |||
| β | p Value | β | p Value | β | p Value | ||||
| 2-SNP haplotype analysis | |||||||||
| rs5993883–rs2239393 | CG | 0.21 | 0.0552 | 0.0828 | 0.0216 | 0.4420 | |||
| rs2239393–rs4680 | GG | 0.32 | 0.0440 | 0.0720 | 0.0119 | 0.4914 | |||
| AA | 0.55 | −0.0320 | −0.0411 | 0.0827 | −0.0207 | 0.3370 | |||
| rs4680–rs4646316 | GA | 0.17 | 0.0434 | 0.0624 | 0.0206 | 0.3950 | |||
| 3-SNP haplotype analysis | |||||||||
| rs5993883–rs2239393–rs4680 | CGG | 0.21 | 0.0548 | 0.0826 | 0.0211 | 0.4569 | |||
| rs2239393–rs4680–rs4646316 | GGA | 0.17 | 0.0433 | 0.0614 | 0.0213 | 0.4311 | |||
Empirical p values based on permutation are reported, with p values <0.05 shown in bold.
Defined by the presence of two out of three possible indicators for high early developmental risk: low birth weight, late motor development and late development of speech.
Haplotype analysis of DRD2 variants on current depressive symptoms (Hopkins Symptom Check List score) in the complete sample from the NFBC 1966
| Gene | Variant | Haplotype | Frequency | Males and females | Males | ||
| β | p Value | β | p Value | ||||
| 2-SNP haplotype analysis | |||||||
| rs4648318–rs4274224 | GG | 0.05 | 0.0409 | 0.0694 | |||
| rs4274224–rs4581480 | GG | 0.07 | 0.0220 | 0.0321 | |||
| AA | 0.48 | 0.0116 | −0.0237 | ||||
| rs4581480–rs7131056 | GA | 0.07 | 0.0220 | 0.0322 | |||
| 3-SNP haplotype analysis | |||||||
| rs4648318–rs4274224–rs4581480 | GGG | 0.05 | 0.0326 | 0.0437 | |||
| rs4274224–rs4581480–rs7131056 | GGA | 0.07 | 0.0215 | 0.0317 | |||
Empirical p values based on permutation are reported, with p values <0.05 shown in bold.
Haplotype analysis of COMT and DRD2 variants on other neurobehavioural traits in the NFBC1966
| Gene | Variant | Group | Gender | HSCL (total) | HSCL (depression) | HSCL (anxiety) | Depression diagnosis | Harm avoidance | |||||
| β | p Value | β | p Value | β | p Value | OR | p Value | β | p Value | ||||
| rs737866 | High risk | Males | 0.0640 | 0.0440 | 0.2239 | 0.0150 | 0.6157 | 0.7130 | 0.5004 | 0.7820 | 0.3799 | ||
| rs5993883-rs2239393 (CG) | High risk | Males | 0.0830 | 0.0750 | 0.0200 | 0.2877 | 0.2100 | 0.1506 | 1.2040 | 0.1433 | |||
| rs4648318-rs4274224 (GG) | All | Males | 0.0694 | 0.0600 | 0.0326 | 0.8280 | 0.6798 | 1.0430 | 0.07009 | ||||
Empirical p values based on permutation are reported, with p values <0.05 shown in bold.
HSCL, Hopkins Symptom Check List.